UNKNOWNPHASE3

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)

Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines: Multi-center, Single Arm, Open, Extension Study

NCT03184363•Daewoong Pharmaceutical Co. LTD.

View on ClinicalTrials.gov

Summary

The purpose of this study is to explore the Efficacy and Safety of DWP450 for treating Crows Feet Lines(CFL) in combination with glabellar line(GL) as extension study of phase 3 study for CFL.

Eligibility

Age

18 - 75 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Male or female of at least 18 to 75 years old
•moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
•moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator
•Subject who has completed phase 3 study for CFL.

Key Dates

Start Date

July 1, 2017

Primary Completion Date

October 1, 2017

Completion Date

December 1, 2017

Last Updated

June 12, 2017

Enrollment

102

ESTIMATED participants

Conditions

Crow's Feet LinesGlabellar Lines

Interventions

Clostridium Botulinum A Toxin

DRUG

A Study to Investigate the Safety and Efficacy of YY003 in Adults with Moderate to Severe Glabellar Lines

NCT06481475

Moderate to Severe Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE2

A Study to Evaluate AI-09 In Participants With Glabellar Lines

NCT07321834

Glabellar Lines

View study

ACTIVE_NOT_RECRUITINGPHASE3

A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 12, 2017Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

NCT06583486

Moderate to Severe Glabellar Lines

View study

COMPLETEDPHASE2